Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 3/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.49 |
| ▸ | TP53 | P04637 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.43 |
| ▸ | PPM1B | O75688 | 1/20 | 0.42 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.42 |
| ▸ | PPP1CC | P36873 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2680062 | 0.90 | CYP3A4 (0.45) | CYP3A4CYP2C19MAPK1TP53SMN1; SMN2 | |
| SCHEMBL1627133 | 0.85 | MAPT (0.42) | CYP3A4CYP2C19MAPK1TP53SMN1; SMN2 | |
| SCHEMBL336940 | 0.84 | CYP3A4 (0.43) | CYP3A4CYP2C19MAPK1TP53SMN1; SMN2 | |
| SCHEMBL18500643 | 0.84 | ALDH1A1 (0.42) | CYP3A4CYP2C19MAPK1TP53SMN1; SMN2 | |
| SCHEMBL14341365 | 0.83 | MAPK1 (0.40) | CYP3A4CYP2C19MAPK1TP53SMN1; SMN2 | |
| SCHEMBL14127636 | 0.82 | CYP3A4 (0.45) | CYP3A4CYP2C19MAPK1TP53SMN1; SMN2 | |
| SCHEMBL30943059 | 0.82 | CYP3A4 (0.44) | CYP3A4CYP2C19MAPK1TP53SMN1; SMN2 | |
| SCHEMBL18500650 | 0.82 | CTSS (0.42) | CYP3A4CYP2C19MAPK1TP53SMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL2070696 | 0.81 | MAPK1 (0.36) | CYP3A4CYP2C19MAPK1TP53SMN1; SMN2 | |
| SCHEMBL24838741 | 0.81 | CYP3A4 (0.47) | CYP3A4CYP2C19MAPK1TP53SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 878 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112430632-B | Preparation method of 2- ((trans) -4-aminocyclohexyl) isopropanol | 上海合全药物研发有限公司 | 2022-09-13 | — | — | CN | claimed |
| EP-3704090-B1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | CALICO LIFE SCIENCES LLC (US) | 2026-05-27 | — | — | EP | disclosed |
| US-12624004-B2 | Opioid receptor agonist, preparation method therefor and pharmaceutical use thereof | FUDAN UNIVERSITY (CN) | 2026-05-12 | — | — | US | disclosed |
| EP-3704096-B1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | CALICO LIFE SCIENCES LLC (US) | 2026-04-22 | — | — | EP | disclosed |
| US-20260092057-A1 | BCL-XL/BCL-2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS INC (US) | 2026-04-02 | — | — | US | disclosed |
| EP-3710428-B1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | CALICO LIFE SCIENCES LLC (US) | 2026-03-25 | — | — | EP | disclosed |
| EP-4714961-A2 | PRODRUG MODULATORS OF THE INTEGRATED STRESS PATHWAY | Calico Life Sciences LLC (US) | 2026-03-25 | — | — | EP | disclosed |
| US-20260069558-A1 | RXFP1 MODULATORS FOR TREATING RESISTANT HYPERTENSION OR HEART FAILURE WITH PULMONARY HYPERTENSION | ASTRAZENECA AB (SE) | 2026-03-12 | — | — | US | disclosed |
| US-20260069559-A1 | COMBINATIONS OF RXFP1 MODULATORS AND SGLT2 INHIBITORS | ASTRAZENECA AB (SE) | 2026-03-12 | — | — | US | disclosed |
| EP-3704125-B1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | CALICO LIFE SCIENCES LLC (US) | 2026-03-11 | — | — | EP | disclosed |
| US-20030225283-A1 | Substituted-cycloalkyl and oxygenated-cycloalkyl glucokinase activators | CORBETT WENDY LEA (US) | 2003-12-04 | — | — | US | disclosed |
| WO-2003095438-A1 | SUBSTITUTED PHENYLACETAMIDES AND THEIR USE AS GLUCOKINASE ACTIVATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2003-11-20 | — | — | WO | disclosed |
| US-6294573-B1 | FOR THERAPY RHEUMATOID ARTHRITIS, OSTEOARTHRITIS, OSTEOPENIAS SUCH AS OSTEOPOROSIS, PERIODONTITIS, GINGIVITIS, CORNEAL, EPIDERMAL OR GASTRIC ULCERATION, AND TUMOR GROWTH AND METASTASIS OR INVASION | ABBOTT LABORATORIES | 2001-09-25 | — | — | US | disclosed |
| EP-0705817-A1 | New cannamide derivatives and their use as allergy inhibitors | TSUMURA & CO. (JP) | 1996-04-10 | — | — | EP | disclosed |
| US-5344845-A | Methyl 4(4-acetoxy-3-methoxycinnamanide and salts as an immunosuppressive drug for allergic reactions | TSUMURA & CO. (JP) | 1994-09-06 | — | — | US | disclosed |
| EP-0535250-A1 | NOVEL COMPOUNDS AND USE THEREOF AS MEDICINE | TSUMURA & CO. (JP) | 1993-04-07 | — | — | EP | disclosed |
| EP-0372817-B1 | NOVEL HETEROCYCLIC PESTICIDAL COMPOUNDS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1992-05-13 | — | — | EP | disclosed |
| US-4985411-A | Insecticides, Acaricides | THE WELLCOME FOUNDATION LTD. (GB) | 1991-01-15 | — | — | US | disclosed |
| EP-0372817-A1 | Novel heterocyclic pesticidal compounds | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1990-06-13 | — | — | EP | disclosed |
| US-4565767-A | Light-sensitive polymer composition with poly(amic acid), bisazide, and tertiary amine compound | HITACHI, LTD (JP) | 1986-01-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260069559-A1 | COMBINATIONS OF RXFP1 MODULATORS AND SGLT2 INHIBITORS | RXFP1, RXFP2, RXFP4 | CYP3A4 4079/4885CYP2C19 3925/4885MAPK1 61/4885 |
| US-12624004-B2 | Opioid receptor agonist, preparation method therefor and pharmaceutical use thereof | OPRM1, OPRD1, OPRK1 | CYP3A4 269/4885CYP2C19 427/4885MAPK1 1360/4885 |
| US-20030225283-A1 | Substituted-cycloalkyl and oxygenated-cycloalkyl glucokinase activators | GCKR, GCK, PDXK | CYP3A4 971/4885CYP2C19 1731/4885MAPK1 2994/4885 |
| US-20260092057-A1 | BCL-XL/BCL-2 DEGRADERS AND USES THEREOF | BCL2L2, BCL2A1, BCL2L1 | CYP3A4 1604/4885CYP2C19 2245/4885MAPK1 2564/4885 |
| US-20260069558-A1 | RXFP1 MODULATORS FOR TREATING RESISTANT HYPERTENSION OR HEART FAILURE WITH PULMONARY HYPERTENSION | RXFP1, RXFP3, RXFP2 | CYP3A4 4753/4885CYP2C19 4572/4885MAPK1 35/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.